Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Two Anti-T-lymphocyte Immune Globulin (ATG-F) Induction Regimens in de Novo Kidney Transplant Patients - a Multicenter, Randomized, Parallel Group Study

NCT02267512 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT02267512
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02267512 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Two Anti-T-lymphocyte Immune Globulin (ATG-F) Induction Regimens in de Novo Kidney Transplant Patients - a Multicenter, Randomized, Parallel Group Study
Lead sponsor
Astellas Pharma Inc
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2012
Completion date
December 31, 2015
Enrollment
280 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

de novo kidney transplant patients